Aavantgarde

Index
Globenewswire

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

Globenewswire

AAVantgarde Presents Updated Positive Clinical Data From its AAVB-081 Program for Usher 1B at EURetina 2025

Globenewswire

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025

Globenewswire

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

Globenewswire

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

Globenewswire

AAVantgarde Presents Positive Clinical Data From its AAVB-081 Program for Usher 1B and Preclinical Data From its AAVB-039 Program for Stargardt at the ARVO 2025 Annual Meeting

Globenewswire

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer